Place an order request to the broker. The personal manager will contact you to confirm the order.

Order Summary

Asset: Select instrument
Quantity: -
Price per Unit: ? This price is indicative and shown for informational purposes only. The final execution price may change. -
Total Amount: -

Order Expiration

Order remains active until you cancel it or it gets filled

Order expires at the end of the selected day

Order Placed Successfully

Your order has been submitted! Our team will contact you shortly to confirm.

Order Type: -
Asset: -
Quantity: -
Total Amount: -
Manually record a past trade to keep your portfolio up to date. This helps track your P&L accurately.
Total Amount: $0.00

Trade Added Successfully

Trade recorded! Your portfolio data will be recalculated.

Type: -
Asset: -
Quantity: -
Price: -
Total: -

Chat Options

Web Search
Search the internet for recent information
Portfolio Context
Include your portfolio in the conversation
Market Data
Access real-time market information
Watchlist Context
Include your watchlist companies

Walmart Inc. (WMT)

2026-09-16T20:18:38.902923+00:00

Key Updates

WMT has declined 2.00% since the 14 September report, retreating from $109.69 to $107.50 and giving back roughly half of the post-earnings rebound that began at the $104.87 trough on 1 September. No incremental earnings or guidance data has been released since the last update; the most recent newsflow (5–10 September) centers on strategic diversification initiatives — a Dunkin'-branded delivery partnership, continued scaling of Walmart Connect advertising, a new "Scenario" fashion label, and strong China omnichannel growth (+20.7%) — alongside confirmation via the 10-Q filing that Q2 FY2027 net income fell 9% YoY to $6.37 billion and diluted EPS declined 9% to $0.80. The opioid lawsuit settlement with the DOJ (28 August) removed a legacy legal overhang without disclosed financial terms.

Current Trend

WMT remains down 3.51% YTD and 14.68% over six months, underscoring a structurally weaker trend despite the recent bounce. The stock is currently trading between the 1 September post-earnings low of $104.87 (support) and the 14 September local high of $109.69 (resistance), having pulled back from the latter. The 5-day return of +1.58% indicates a mild stabilization attempt, but the 1-day (-0.55%) and 1-month (-5.97%) figures confirm that downside momentum from the 20 August earnings miss has not been fully resolved.

Investment Thesis

The core thesis rests on Walmart's scale, omnichannel execution, and diversification into higher-margin adjacencies (advertising, e-commerce, membership, international) to offset decelerating core U.S. comparable sales. Q2 FY2027 confirmed 6% consolidated revenue growth alongside e-commerce growth of 24% and Walmart Connect advertising growth of 43%, but U.S. comparable sales growth slowed to 2.6% — a six-year low — driven primarily by pharmacy headwinds tied to Medicare drug-price regulation. Management has responded by raising full-year sales guidance to 4-5% while simultaneously lowering near-term EPS visibility, reflecting confidence in top-line resilience but caution on margin trajectory.

Thesis Status

The thesis remains structurally intact but under near-term pressure. Diversification drivers (China +20.7%, advertising +43%, e-commerce +24%) continue to validate the long-term growth narrative, and management's pricing and delivery expansion strategy (11,000 item price cuts, Dunkin' delivery integration) reinforces the traffic-and-market-share thesis. However, the 9% YoY decline in net income and EPS, confirmed in the 10-Q, alongside softer Q3 EPS guidance ($0.62-$0.64 vs. consensus $0.68), indicates margin compression is a live risk. The stock's failure to sustain the recovery above $109.69 suggests the market has not fully re-rated the stock post-earnings, keeping the thesis in a "wait-and-confirm" state pending Q3 results.

Key Drivers

  • Q2 FY2027 10-Q confirms 6% revenue growth but 9% YoY decline in net income and EPS — SEC EDGAR
  • Pharmacy pressure from Medicare drug-price regulation persists as a structural headwind into 2026 — Forbes
  • Diversification into restaurant delivery (Dunkin', Subway) leverages logistics scale to compete with DoorDash/Uber Eats — CNBC
  • Advertising business (Walmart Connect) scaling with ~70% margins and 150 million weekly shoppers — Morningstar
  • China segment delivering 20.7% sales growth via omnichannel model, outpacing U.S. growth by a wide margin — Fortune
  • DOJ opioid lawsuit settlement removes legal overhang, though terms undisclosed — CNBC

Technical Analysis

WMT is consolidating within a $104.87–$109.69 range established since the 20 August earnings-driven selloff. The current price of $107.50 sits near the midpoint of this range, with the 5-day uptrend (+1.58%) suggesting near-term support is holding above the September low, while resistance remains at the $109.69 level tested on 14 September. A break above resistance would signal renewed recovery momentum; failure to hold above $104.87 support would reopen downside risk toward the YTD trend low. The broader 6-month decline of -14.68% confirms the primary trend remains bearish despite short-term stabilization.

Bull Case

  • Full-year sales growth guidance raised to 4-5% from 3.5-4.5%, reflecting management confidence despite the Q2 comp miss — Reuters
  • Walmart Connect advertising revenue tripled over four years to $6.4 billion with ~70% margins, diversifying earnings mix away from low-margin retail — Morningstar
  • China business growing 20.7%, more than 7x the U.S. comp rate, with over 50% of sales now online — Fortune
  • E-commerce growth of 24% and fast delivery (under 30 minutes) up 48%, supporting omnichannel market share gains, including among higher-income households — Fortune
  • Expected $2.9 billion in tariff refunds supporting gross margin expansion (+96bps) and funding price investment strategy — Morningstar

Bear Case

  • Net income fell 9% YoY to $6.37 billion and diluted EPS declined 9% to $0.80, confirmed in the official 10-Q filing, indicating margin compression — SEC EDGAR
  • U.S. comparable sales growth of 2.6% marks the slowest pace in six years, missing consensus of 3.5-3.8% — described as "one of the biggest misses in years" — CNBC
  • Pharmacy headwinds from Medicare drug-price regulation expected to persist into 2026, with an additional $2 billion cost headwind projected from higher fuel prices — Forbes
  • Q3 EPS guidance of $0.62-$0.64 falls below analyst consensus of $0.68, signaling continued near-term profitability pressure — Reuters
  • Average transaction value growth slowed to 1.1% from 3.1% YoY, indicating consumer pullback on discretionary spending amid rising gas prices — Reuters

CapPilot is AI-powered and can make mistakes. Please double-check responses.

CapPilot leverages generative AI to distill market insights and analysis, as well as answer your questions in chat. While we work hard to ensure accuracy, AI-generated content may occasionally contain inaccuracies or outdated information.

We value your feedback — reporting errors helps us continuously improve.